These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36624161)

  • 1. Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
    Srour M; Alsuliman T; Labreuche J; Bulabois CE; Chevallier P; Daguindau E; Forcade E; François S; Guillerm G; Coiteux V; Turlure P; Beguin Y; Yakoub-Agha I; Magro L
    Bone Marrow Transplant; 2023 Apr; 58(4):401-406. PubMed ID: 36624161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study.
    Chen T; Li J; Wei X; Yao H; Zhu L; Liu J; Liu Y; Wang P; Feng Y; Gao S; Liu H; Wang L; Zhao L; Gao L; Zhang C; Gao L; Zhang X; Kong P
    Acta Haematol; 2024; 147(5):499-510. PubMed ID: 38232716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.
    Chen GL; Carpenter PA; Broady R; Gregory TK; Johnston LJ; Storer BE; Beumer JH; Qiu J; Cerda K; Le R; Otani JM; Liu H; Ross MA; Arai S; Flowers MED; McCarthy PL; Miklos DB
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):373-380. PubMed ID: 29051021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
    Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
    Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease.
    Choi JY; Kim H; Baek HJ; Kook H; Lee JM; Kim BK; An HY; Hong KT; Shin HY; Kang HJ
    Transplant Cell Ther; 2021 Nov; 27(11):925.e1-925.e7. PubMed ID: 34314892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial.
    Cortes JE; De Souza CA; Ayala M; Lopez JL; Bullorsky E; Shah S; Huang X; Babu KG; Abdulkadyrov K; de Oliveira JSR; Shen ZX; Sacha T; Bendit I; Liang Z; Owugah T; Szczudlo T; Khanna S; Fellague-Chebra R; le Coutre PD
    Lancet Haematol; 2016 Dec; 3(12):e581-e591. PubMed ID: 27890073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
    Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
    Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease.
    Zerr P; Distler A; Palumbo-Zerr K; Tomcik M; Vollath S; Dees C; Egberts F; Tinazzi I; Del Galdo F; Distler O; Schett G; Spriewald BM; Distler JH
    Am J Pathol; 2012 Nov; 181(5):1672-80. PubMed ID: 22940072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
    Cortes JE; Hochhaus A; le Coutre PD; Rosti G; Pinilla-Ibarz J; Jabbour E; Gillis K; Woodman RC; Blakesley RE; Giles FJ; Kantarjian HM; Baccarani M
    Blood; 2011 May; 117(21):5600-6. PubMed ID: 21467546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.
    Sánchez-Ortega I; Parody R; Servitje O; Muniesa C; Arnan M; Patino B; Sureda A; Duarte RF
    Croat Med J; 2016 Jun; 57(3):247-54. PubMed ID: 27374826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective.
    Molés-Poveda P; Montesinos P; Sanz-Caballer J; de Unamuno B; Piñana JL; Sahuquillo A; Botella-Estrada R
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):241-247. PubMed ID: 29254596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib for refractory chronic graft-versus-host disease with fibrotic features.
    Olivieri A; Locatelli F; Zecca M; Sanna A; Cimminiello M; Raimondi R; Gini G; Mordini N; Balduzzi A; Leoni P; Gabrielli A; Bacigalupo A
    Blood; 2009 Jul; 114(3):709-18. PubMed ID: 19403889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
    Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
    Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
    Giles FJ; le Coutre PD; Pinilla-Ibarz J; Larson RA; Gattermann N; Ottmann OG; Hochhaus A; Radich JP; Saglio G; Hughes TP; Martinelli G; Kim DW; Novick S; Gillis K; Fan X; Cortes J; Baccarani M; Kantarjian HM
    Leukemia; 2013 Jan; 27(1):107-12. PubMed ID: 22763385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
    Sánchez-Ortega I; Servitje O; Arnan M; Ortí G; Peralta T; Manresa F; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):318-23. PubMed ID: 22068151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nilotinib after imatinib first-line: a real-life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase.
    Cony-Makhoul P; Gardembas M; Coiteux V; Carpentier N; Pommier C; Violet I; Quittet P; Berger MG;
    Br J Haematol; 2018 Feb; 180(3):356-364. PubMed ID: 29265184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
    Griffin JD; Guerin A; Chen L; Macalalad AR; Luo J; Ionescu-Ittu R; Wu EQ
    Curr Med Res Opin; 2013 Jun; 29(6):623-31. PubMed ID: 23517347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.